Kornimate/medical-research-clean huggingface dataset:
esketamine combined pulsed radiofrequency for acute/subacute zoster-associated trigeminal neuralgia

Conditions: Zoster; Herpes, Trigeminal Neuralgia (Etiology)

Summary: to assess the 1-month effects and safety of esketamine combined prf and standardized treatment to relieve pain in patients with acute/subacute zoster-related trigeminal neuralgia(zrtn).

the investigators aim to investigate whether or not esketamine combined prf and standardized treatment to relieve pain in patients with acute/subacute zrtn , and seek a safe, and effective treatment for refractory patients with zrtn

Eligibility criteria:
inclusion criteria: 1. age \>18 years; 2. history of hz within the last three months; 3. lesions located in the trigeminal nerve or its branches innervated regions； 4. numeric rating scale (nrs) pain score≥4 (nrs, 0 = no pain, 10= worst possible pain) with pharmacotherapy; 5. planned to perform ct-guided prf treatment of the gasserian ganglion . exclusion criteria: 1. obstructive sleep apnoea syndrome; 2. those who receive other invasive treatments, such as spinal cord stimulation; 3. a history of systemic immune diseases, organ transplantation, or cancers; 4. a history of severe cardiopulmonary, hepatic or renal dysfunction; 5. a history of schizophrenia, epilepsy, or myasthenia gravis, delirium; 6. comorbid hyperthyroidism or phaeochromocytoma; 7. recent history of drug abuse; 8. having contraindications to esketamine; 9. communication difficulties. withdrawal criteria 1. lost to follow-up during the study; 2. not perform the planned operation; 3. receiving other treatment regimes during the study period; 4. not suitable for continuing the study for emerging severe comorbidities or special physiological changes during the study; 5. voluntary withdrawal from the study.

Keywords: acute/subacute zoster-associated trigeminal neuralgia esketamine pulsed radiofrequency
prognostic study of hpv virus integration in women with hsil

Conditions: HPV Infection; Virus Integration; HSIL, High Grade Squamous Intraepithelial Lesions

Summary: human papillomavirus (hpv) is currently one of the most common sexually transmitted infections, according to its carcinogenicity is divided into high-risk genotypes and low-risk genotypes, research has confirmed that carcinogenic hpv type continuous infection leads to a higher incidence of condyloma acuminatum and cervical cancer, while increasing the oropharyngeal cancer, vaginal cancer and other related cancer risk. based on clinical practice, the purpose of this study was to: 1) identify the correlation between hpv integration and the outcome of disease in hsil women. 2) to determine the prognostic value of different hpv gene integration status in hsil women. 3) to clarify the relationship between different hpv gene integration status and diversity of vaginal flora in hsil women.

a total of 1000 women with hsil were recruited from multiple centers. in this prospective cohort study, 4 samples of cervical exfoliated cells and fornix secretions were collected at enrollment, 6 months, 12 months and 24 months for hpv integration status and vaginal flora diversity sequencing, and 2 samples of peripheral blood (whole blood and serum) were collected at enrollment. the effects of hpv integration status and microbiota changes on the outcome and progression of hsil were evaluated.

Eligibility criteria:
inclusion criteria: * pathologically confirmed hsil(cin2, 3) in women or cervical carcinoma in situ or early invasive cancer; * no surgical treatment or conization only; * obtain informed consent. exclusion criteria: * during pregnancy or lactation; * patients with a history of genital tract cancer; * previous history of hysterectomy, cervical surgery or pelvic radiotherapy; * received treatment related to genital tract infection, hpv or other stds pathogen infection in the past one month; * use of antibiotics or vaginal microecological improvement products in the past 1 month.
irisin hormone levels in endometrial hyperplasia

Conditions: Endometrial Hyperplasia

Summary: the purpose of the study is to determine serum irisin hormone levels an its relation between endometrial hyperplasia

the study consisted of two groups. the first group was formed of the patients diagnosed endometrial hyperplasia histopathologically , and the controls were healthy women admitted to the clinic just for annual examination without any complain and symptoms. patients in the 35-50 age range in both groups were included in the study. the histopathologic diagnosis of patients was established for kayseri education and research hospital pathology clinics. demographic parameters such as age, menopausal status, body mass index (bmi), body weight and known familial cancer story were registered. pregnancy, liver function disorders, cardiovascular disease, metabolic disease, diabetes, chronic kidney disease, central nerves system disease, immunosuppressive drug use, another known malignancy and excessive exercises in among one month were all exclusion criteria for the patients. 3 cc peripheral venous blood samples were taken in the patients' diagnosed endometrial hyperplasia in the course of evaluation the biopsy results and in controls during their examinations just for only once. blood samples were centrifuged in 3200 rpm speed for 10 minutes, and stored in -80 'c until the analysis. blood samples were evaluated on the same day after four mounts for stored first blood sample. serum irisin levels were evaluated with enzyme- linked immunosorbent assays kit (catalog number: k4761-100 biovision usa) in kayseri research and education hospital biochemical clinics.

Eligibility criteria:
inclusion criteria: * between 35-50 years of age * i̇n endometrial hyperplasia group; patients who were diagnosed endometrial hyperplasia histopathologically exclusion criteria: * pregnancy * liver function disorders * cardiovascular disease * metabolic disease * diabetes * chronic kidney disease * central nerves system disease * immunosuppressive drug use * another known malignancy * excessive exercises in among one month

Keywords: endometrial hyperplasia irisin fibronectin type iii domain containing 5 fndc5 (fibronectin type iii domain containing )
trifluridine/tipiracil plus bevacizumab versus trifluridine/tipiracil monotherapy in refractory metastatic colorectal cancer

Conditions: Metastatic Colorectal Adenocarcinoma

Summary: this study is a retrospective study to compare the efficacy and safety between trifluridine/tipiracil (tas-102) plus bevacizumab (bev) with tas-102 monotherapy in refractory metastatic colorectal cancer (mcrc) from november 2020 to october 2022 at the hunan cancer hospital.

our retrospective analysis was conducted to explore the efficacy and safety of patients treated with at least 1 cycle of tas-102 with or without bev in patients suffering refractory mcrc from november 2020 to october 2022 at the hunan cancer hospital. data from the electronic medical records were the sources. in tas-102 monotherapy group, tas-102 35 mg/m²orally twice a day on days 1-5 and 8-12, every 28 days were given to patients, while on days 1 and 15, every 28 days, patients received bevacizumab (5 mg /kg, intravenously) in tas-102 plus bev group. the median os (mos) was the primary end point.while mpfs, the orr, the disease control rate(dcr) and the incidence of treatment-related adverse events (traes) were the secondary end points.

Eligibility criteria:
inclusion criteria: * 1.has histologically confirmed unresectable adenocarcinoma of the colon or rectum (all other histological types are excluded). 2. have progressed from at least 2 lines of standard treatment,including fluoropyrimidines, irinotecan, oxaliplatin, with or without targeted drugs, like bevacizumab and cetuximab (only for ras wild-type). fruquintinib or regorafenib was permitted but not required for inclusion. 3.has measurable or non-measurable disease as defined by recist version 1.1 4.is able to swallow oral tablets. 5.estimated life expectancy ≥12 weeks. 6.eastern cooperative oncology group performance status (ecog ps) 0 or 1 7. has adequate organ function. exclusion criteria: * 1.pregnancy, lactating female or possibility of becoming pregnant during the study. 2.has not recovered from clinically relevant non-hematologic ctcae grade ≥ 3 toxicity of previous anticancer therapy (excluding alopecia, and skin pigmentation). 3.has symptomatic central nervous system metastases that are neurologically unstable or requiring increasing doses of steroids to control cns disease. 4.has severe or uncontrolled active acute or chronic infection. 5.known carriers of hiv antibodies. 6.confirmed uncontrolled arterial hypertension or uncontrolled or symptomatic arrhythmia.

Keywords: colorectal cancer; trifluridine/tipiracil ; bevacizumab
improved preoperative selection of cold thyroid nodules

Conditions: Thyroid Nodules

Summary: molecular gene profiling of fine-needle aspiration samples in addition to fine-needle aspiration cytology can improve the selection of patients with benign versus malignant thyroid nodules with improved sensitivity.


Eligibility criteria:
inclusion criteria: * solitary thyroid nodules that appear solid on ultrasound and cold on a scintiscan exclusion criteria: * pregnancy and lactation * age below 20 years

Keywords: solitary solid and scintigraphically cold thyroid nodules
effects of cervical extension traction with & without modified cervical and shoulder retraction exercises in neck pain

Conditions: Neck Pain

Summary: the study aims to explore whether the modified cervical and shoulder retraction exercise program restores cervical sagittal alignment and reduces neck pain in patients with non-specific neck pain.

neck pain is a musculoskeletal system disorder that causes social and economic loss by reducing the quality of life (qol) of the individual, and its prevalence varies from 16.7 to 75.1% in the adult population. non-specific neck pain (nnp) is a symptom related to a postural or mechanical cause. nnp is also associated with loss of cervical curvature. in healthy spines, the axial load along the cervical spine is supported along the ventral column of the spine. however, in spines with the loss of lordosis, the load moves more anteriorly, which causes neck pain. cervical exercise has been shown to be an effective treatment for neck pain and cervical alignment, but there is still a need for more clinical trials evaluating the effectiveness of the exercise approach. it seems reasonable to assume that naturally good neck muscle strength and range of motion are likely to be protective factors against neck pain. as per previous research, the effects of exercise therapy on non-specific neck pain have been examined but there is limited literature available for use of cervical and shoulder retraction exercises in patients with nonspecific neck pain. most of the studies have been done with neck isometrics, manual mobilization, and deep cervical flexors training and there is less scope of practicing cervical extension traction in contrast with modified cervical and shoulder retraction exercises. previous research is limited by no use of a control group in a modified retraction exercise regime. to fill this literature gap this study is proposed which will focus on the clinical significance of modified cervical and shoulder retraction exercises on pain, disability, and cobb's angle in the management of non-specific neck pain.

Eligibility criteria:
inclusion criteria: * neck pain history * patients with lateral cervical radiograph * patients who agreed for a follow up of 6 weeks exclusion criteria: * congenital abnormalities e.g. torticollis * past surgical history of cervical spine * positive vbi sign * patients with inflammatory or rheumatic diseases * already undergoing physiotherapy treatment

Keywords: neck pain retraction disability cervical traction
effects of interdental brush dipped in 0.2% hyaluronic acid gel on periodontitis

Conditions: Periodontitis

Summary: this study aimed to compare the effects of using an interdental brush dipped in 0.2% ha gel with those of using a regular interdental brush on clinical periodontal parameters following srp among patients with periodontitis.

the additional use of agents with antibacterial and anti-inflammatory activities such as hyaluronic acid (ha) in treating periodontal disease has recently become popular. this study aimed to evaluate the effects of using an interdental brush dipped in 0.2% ha gel on clinical periodontal parameters.this randomized controlled trial was conducted among 33 female patients and 27 male patients with stage ii/iii grade a/b periodontitis. after the initial periodontal treatment, patients were randomly divided into two groups; those in the test group were asked to use an interdental brush dipped in 0.2% ha gel twice a day after brushing, while those in the control group were asked to use a regular interdental brush. clinical periodontal parameters including the pocket depth, clinical attachment loss, gingival index, plaque index, and papillary bleeding index (pbi) were assessed at baseline and in the 1st and 3rd months after treatment.

Eligibility criteria:
inclusion criteria: 1. ≥18-55 years of age 2. being systemically healthy 3. having periodontitis (stage 3) 4. not to have used any medication in the last three months 5. not smoking 6. right-handed 7. at least 20 natural teeth exclusion criteria: 1. patients with interdental caries 2. patients with orthodontic appliances 3. patients with removable (partial) prostheses 4. patients with oral and/or peri-oral pain 5. patients with significant oral lesions 6. patients with antibiotic use in the last 3 months, pregnancy and breastfeeding 7. patients who have undergone periodontal treatment within the last 6 months

Keywords: periodontitis hyaluronic acid oral hygiene
velocity: a study to characterize real-world outcomes of spinal cord stimulation

Conditions: Chronic Pain

Summary: the primary objective of this study is to characterize the real-world outcomes of spinal cord stimulation (scs) therapy as an aid in the management of chronic intractable pain of the trunk, including unilateral or bilateral pain associated with the following: failed back surgery syndrome, intractable low back pain using the boston scientific (bsc) precision spinal cord stimulator system with multiwave technology.

the purpose of this study is to characterize the real-world outcomes of spinal cord stimulation (scs) therapy as an aid in the management of chronic intractable pain of the trunk, including unilateral or bilateral pain associated with the following: failed back surgery syndrome, intractable low back pain using the boston scientific (bsc) precision spinal cord stimulator system with multiwave technology.

Eligibility criteria:
key inclusion criteria: * complaint of persistent or recurrent low back pain for at least 180 days prior to screening * willing and able to comply with all protocol-required procedures and assessments/evaluations * subject signed a valid, ethics committee (ec)-approved informed consent form (icf) provided in local language key exclusion criteria: * high surgical risk * previous spinal cord stimulation trial or is already implanted with an active implantable device(s) (e.g. pacemaker, drug pump, implantable pulse generator) * a female who is pregnant, is breastfeeding, or is of childbearing potential and planning to get pregnant during the course of the study or not using adequate contraception. * participating (or intends to participate) in another drug or device clinical trial that may influence the data that will be collected for this study * any diagnosis or condition that, in the clinician's best judgment, might confound reporting of study outcomes

Keywords: spinal cord stimulation chronic pain
a study of phn-010 in patients with advanced solid tumors

Conditions: Lung Cancer; Colon Cancer; Endometrial Cancer; Ovarian Cancer; Cervical Cancer; Advanced Solid Tumor; Advanced Cancer

Summary: this first-in-human study will evaluate safety, tolerability, anti-tumor activity, immunogenicity, pharmacokinetics and pharmacodynamics of phn-010, a novel antibody-drug conjugate (adc), in patients with advanced solid tumors.


Eligibility criteria:
key inclusion criteria: * has histologically confirmed, advanced/metastatic: 1. colorectal adenocarcinoma (crc), or 2. serous, endometroid, or clear-cell epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer, or 3. serous, endometroid or clear-cell endometrial cancer, or 4. adenocarcinoma or squamous-cell carcinoma of the cervix, or 5. non-small cell lung cancer (nsclc). * has received at least one prior systemic therapy and radiologically or clinically determined progressive disease during or after the most recent line of therapy, and for whom no further standard therapy is available or who is intolerant to standard therapy. * has measurable disease. * eastern cooperative oncology group (ecog) performance status of 0 or 1. * has adequate organ function. * has available tumor tissue sample at screening (either an archival specimen collected ≤ 3 years prior to the date of informed consent or fresh biopsy material). exclusion criteria: * had prior treatment with any adc containing topoisomerase-1 inhibiting payload. * has unstable central nervous system metastasis. * has persistent toxicities from previous systemic anti-cancer treatments of grade \>1. * has received systemic anti-neoplastic therapy within five half-lives or 21 days, whichever is shorter, prior to first dose of the study drug. * has received wide-field radiotherapy (\> 30% of marrow-bearing bones) within 28 days, or focal radiation for analgesic purpose or for lytic lesions at risk of fracture within 14 days prior to first dose of the study drug, or no recovery from side effects of such intervention. * had major surgery (not including placement of vascular access device or tumor biopsies) within 28 days prior to first dose of the study drug, or no recovery from side effects of such intervention. * has acute and/or clinically significant bacterial, fungal, or viral infection including hepatitis b (hbv), hepatitis c (hcv), known human immunodeficiency virus (hiv). * has a history of non-infectious pneumonitis (nip) / interstitial lung disease (ild) requiring systemic steroids, active nip / ild or suspected nip / ild which cannot be ruled out by imaging for screening. other protocol defined inclusion/exclusion criteria apply.

Keywords: antibody-drug conjugate carcinoma cancer solid tumor
negative pressure wound therapy in traumatic skin loss

Conditions: Post Traumatic Skin Loss

Summary: assessment of the effectiveness of negative pressure wound therapy on post-traumatic wounds, as regard to : * the period of granulation tissue formation. * the infection rate in npwt in comparison to conventional dressing. * the rate of graft take after npwt. * the length of hospital stay.

over the last 15 years, negative-pressure wound therapy "npwt" has become commonly used for treatment of a wide variety of complex wounds. many clinicians have noted a dramatic response when negative-pressure wound therapy technology has been used, prompting a number of scientific investigations related to its mechanism of action and clinical trials determining its efficacy. npwt is a modality that has shown great promise and delivered significantly better results in the clinical care of acute as well as chronic wounds. it is designed to seal the wound site using foam dressing linked to an electronic pump, which applies a pressure ranging from -75 to -150 mmhg. as a matter of fact, npwt's impact on wound healing appears to be the consequence of multiple effects, each contributing to the overall positive influence on wound healing. current research indicates that there are four primary npwt mechanisms of action: macrodeformation, microdeformation, fluid removal and environmental control of the wound. even if the role of npwt in promoting wound healing has been largely accepted, there is a lack of evidence (few high-level clinical studies) regarding its effectiveness and further research is needed to better understand the mechanisms of action. traumatic wounds vary from abrasions and minor skin incisions or tears to wounds with extensive tissue damage or loss and damage to bone and internal organs. delayed wound healing particularly in difficult wounds is a major concern, it leads to pain, morbidity, prolonged treatment, and require major reconstructive surgery which imposes enormous social and financial burden.

Eligibility criteria:
inclusion criteria: * no age preference. * no gender preference. * acute traumatic wounds. * admitted to the hospital. exclusion criteria: * exposed vessels, nerves \& organs. * active bleeding. * ischemic limb. * opening into body cavity. * vulnerable body organs. * necrotic tissue with eschar present.
peco air purification in hospital rooms to improve health outcomes for pediatric respiratory distress

Conditions: Asthma; Pneumonia; Respiratory Distress Syndrome

Summary: this study will investigate the efficacy of a novel air purification technology, photo electrochemical oxidation (peco), has on pediatric patients hospitalized for respiratory distress. the study will take place at mercyhealth hospital - rockton avenue where all 23 pediatric rooms will be outfitted with portable peco air purifying units. the main outcomes are the length of stay and progression to icu, which will be compared with historical controls.

the goal of this study is to assess whether using peco to purify air in a hospital can improve health outcomes for pediatric patients with respiratory distress. the results of this study will be used in three primary ways: 1. as evidence to support an installation of peco in hospital hvac systems to improve the standard of care for patients with respiratory distress 2. towards dissemination efforts through publication in a peer-reviewed journal and presentation at national and international conferences 3. for informing healthcare providers and stakeholders there are no plans to repeat this study with other hospital partners

Eligibility criteria:
inclusion criteria: all pediatric patients who are admitted to the mercyhealth hospital - rockton avenue following the start date and have infectious or non-infectious respiratory distress as defined by the following icd codes will be included in the study: * j00-j06: acute upper respiratory infections * j09-j18: influenza and pneumonia * j20-j22: other acute lower respiratory infections * j30-j39: other diseases of upper respiratory tract * j40-j47: chronic lower respiratory diseases * j60-j70: lung diseases due to external agents * j80-j84: other respiratory diseases principally affecting the interstitium * j85-j86: suppurative and necrotic conditions of the lower respiratory tract * j90-j94: other diseases of the pleura * j95-j95: intraoperative and postprocedural complications and disorders of respiratory system, not elsewhere classified exclusion criteria: * any patient admitted to the nicu * patients in the er only * any patient with non-respiratory conditions * adults

Keywords: asthma environmental intervention respiratory distress pediatric hospitalization pneumonia bronchiolitis